Pharma channel feed – Endpoints News

Pharma channel feed

With its back against the wall, Regulus hands over its lead microRNA drug to Sanofi for a small down payment

7 years ago

Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster star Dupixent

7 years ago

Bargain sale continues: AstraZeneca offloads three respiratory drugs to Covis in $350M deal

7 years ago

After playing possum in I/O, Eli Lilly shows new signs of life with $40M-plus cash discovery deal for NextCure

7 years ago

Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use

7 years ago

Need alternative funding channels? Perceptive Advisors now has $675M devoted to those deals

7 years ago

In another try at lung cancer niche, J&J nabs a potential Tagrisso rival for $50M-plus

7 years ago

Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price

7 years ago

Sage appears set for a breakthrough FDA OK on postpartum depression drug, but who’s going to use it?

7 years ago

Tripped up by the FDA, Novartis says it is dropping out of the US race to win an OK for a blockbuster Rituxan rival

7 years ago

Pfizer racks up its third cancer drug OK in 2 months, but is it enough to replace regular price hikes?

7 years ago

Trevena hammered again as the FDA spurns their controversial pain drug — but AcelRx gets a green light

7 years ago

J&J dumps PhII-ready CD28 autoimmune asset, returns rights to French partner

7 years ago

Illumina forks out $1.2B to buy rival Pacific Biosciences, placing long and short-read DNA tech under the same roof

7 years ago

FDA experts gun down Alkermes’ pitch for ALKS-5461, slamming the company on multiple fronts

7 years ago

FDA preps for a new and flexible approach to genome editing in animals

7 years ago

GW's cannabis-derived drug Epidiolex finally launches in the US with an average list price of $32,500

7 years ago

6 months after arriving at Sanofi R&D, John Reed gambles $125M on Denali’s RIPK1 work

7 years ago

FDA staff suggests safety profile of Sage postpartum depression drug disqualifies it from at-home infusions

7 years ago

Weeks after launching Aeterna Zentaris castoff, Strongbridge turns around and sells rights to Novo Nordisk — at a premium

7 years ago

Arch Venture sets its sights on raising $600M for Fund X

7 years ago

Problems, problems, problems: But Alkermes will fight it out this week over the FDA’s objections to its big depression drug ALKS 5461

7 years ago

AstraZeneca hands over some rights to Nexium, Vimovo to Grünenthal as it plots turnaround

7 years ago

TherapeuticsMD wins FDA nod for hormone therapy, capping off drugmaker's prolific year

7 years ago

First page Previous page 287 288 289290291 292 293 Next page Last page